Solventum Corp (SOLV) stock
SOLVNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3089% above fair value
$86.48+0.42 (+0.49%)
Close on Nov 18, 2026Market cap $14.72BP/E 97.2Yield –
Solventum free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Solventum's free cash flow for the twelve months ending Sep 30, 2026 was $0, down 100.0% year over year. For fiscal 2025 it was -$10.00M, down 101.2% from the year before.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.00M | -101.2% |
| FY2024 | Dec 31, 2024 | $805.00M | -50.5% |
| FY2023 | Dec 31, 2023 | $1.63B | +13.8% |
| FY2022 | Dec 31, 2022 | $1.43B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $97.00M | – |
| Q2 FY2026 | Jun 30, 2026 | $144.00M | +144.1% |
| Q1 FY2026 | Mar 31, 2026 | -$273.00M | – |
| Q4 FY2025 | Dec 31, 2025 | $32.00M | -65.2% |
| Q3 FY2025 | Sep 30, 2025 | -$21.00M | -127.6% |
| Q2 FY2025 | Jun 30, 2025 | $59.00M | -80.1% |
| Q1 FY2025 | Mar 31, 2025 | -$80.00M | -123.5% |
| Q4 FY2024 | Dec 31, 2024 | $92.00M | -80.0% |
| Q3 FY2024 | Sep 30, 2024 | $76.00M | -82.2% |
| Q2 FY2024 | Jun 30, 2024 | $297.00M | +0.7% |
| Q1 FY2024 | Mar 31, 2024 | $340.00M | -23.4% |
| Q4 FY2023 | Dec 31, 2023 | $459.00M | – |
| Q3 FY2023 | Sep 30, 2023 | $427.00M | – |
| Q2 FY2023 | Jun 30, 2023 | $295.00M | – |
| Q1 FY2023 | Mar 31, 2023 | $444.00M | – |
See a number that looks wrong?